Form 4: Immunovant Executive Sells Shares to Cover Tax Obligations

Julia G. Butchko, Chief Development Officer of Immunovant, Inc., sold 1,053 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On April 9, 2024, Julia G. Butchko, Chief Development Officer of Immunovant, Inc., sold 1,053 shares of Immunovant's common stock.
• The sale was executed to cover tax withholding obligations associated with the vesting of 3,406 restricted stock units (RSUs) on April 1, 2024.
• The shares were sold at a weighted average price of $31.18, with individual transactions ranging from $30.73 to $31.45 per share.
• Following the transaction, Butchko directly owns 461,742 shares of Immunovant common stock.
• The sale was mandated by Immunovant's policy requiring tax obligations to be funded through a 'sell to cover' transaction.

Sentiment

Score: 5

Explanation: This is a neutral event. It's a routine transaction to cover tax obligations and doesn't necessarily indicate a positive or negative outlook on the company.

Industry Context

Form 4 filings are a routine part of the financial markets, providing transparency into the transactions of company insiders. This particular filing reflects a standard practice of executives selling shares to cover tax obligations arising from the vesting of equity awards.

Key Dates